4783-89-5

Basic information

• Product Name: Pyridine, 4-(3-nitrophenoxy)-
• CAS NO: 4783-89-5
• Molecular Formula: C11H8N2O3
• Molecular Weight: 216.196
• Mol File: 4783-89-5.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Pyridine, 4-(3-nitrophenoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 4-(3-nitrophenoxy)-(4783-89-5)
• EPA Substance Registry System: Pyridine, 4-(3-nitrophenoxy)-(4783-89-5)

Safety Data

• Hazardous Substances Data: 4783-89-5(Hazardous Substances Data)

Upstream product

• 554-84-7 meta-nitrophenol 
• 56201-88-8 [1,4']bipyridylium; hydrobromide 
• 626-64-2 pyridin-4-ol 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 626-61-9 4-Chloropyridine 
• 5421-92-1 1-(4-pyridyl)pyridinium chloride hydrochloride 

Downstream Products

• 102877-77-0 3-(pyridin-4-yloxy)aniline 

Relevant articles and documents

AKT3 MODULATORS

Compounds of Formula la, lb, or Ic,, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS

The present invention relates to benzimidazole carboxamides of formula (I), the use of the compounds of formula (I) as inhibitors of as inhibitors of one or more kinases, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase phathways, preferably by the raf kinase pathway, especially cancers.

MALONAMIDE DERIVATIVES

The present invention relates to malonamide derivatives of formula (I): A-D-B, the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.